Investors who want to play the really interesting stories in med-tech have to be ready to act fast or step up when times look uncommonly tough. That's about the only way to get a decent valuation on stocks like Intuitive Surgical (Nasdaq:ISRG), Cepheid (Nasdaq:CPHD) or Illumina (Nasdaq:ILMN), and that seems largely true for animal and food safety specialist Neogen (Nasdaq:NEOG). Although valuation and earnings quality are still problematic here, these shares also highlight the importance of being up-to-date on research and able to pull the trigger quickly.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

A Disappointing Second Quarter
Although Neogen doesn't generally step far out of line, this quarter was a notable exception. Revenue rose just 2% this quarter, not only missing the averaged estimate but missing the low-end estimate as well. Animal safety revenue was up just 1%, due at least in part to lower activity in the GeneSeek agricultural genomics business. Food safety was hardly stellar, though, as revenue was up just over 3% this quarter.

Profits were even more disappointing than growth. Gross margin slid almost a point, and management blamed it on a mix shift (which would be consistent with lower sales of more profitable genomics services). Operating income fell 16% and operating margin four points as the company put more money into its sales and marketing efforts in the hopes of driving better revenue growth. (For related reading, see A Primer On The Biotech Sector.)

Mostly Just a Pause
There could be plenty of explanations for this quarter's poor performance that don't ding the long-term story. The company is annualizing tough comps from myotoxin testing in corn and there are rumors that there's another poor quality crop out there that could boost sales later in this fiscal year.

At the same time, the company is seeing some momentum in other kinds of toxin testing and will soon be pushing the ANSR molecular diagnostics platform for foodborne pathogens. This ANSR could be an interesting platform and grab business from the likes of Bio-Rad (NYSE:BIO) as it offers a simple and quick testing methodology that's easy on equipment and labor.

There's also the question of the genomics business. Neogen is partnered with Illumina and seems to be seeing some of the same problems - including lower government spending and a tough European markets. Longer term, though, it's easy to be bullish on agrigenomics even with companies like Life Technologies (Nasdaq:LIFE) and Luminex (Nasdaq:LMNX) active in the space.

Still Some Issues to Resolve
Neogen's stock may have overreacted to one quarter's disappointment, but then a lot is baked into the price. Neogen generates good returns on capital, but a lot of its growth has long been dependent on serial acquisitions. For a company that needs to prove it can produce organic double-digit growth, this quarter was a definite setback.

Valuation is likewise an issue. Not unlike Meridian Bioscience (Nasdaq:VIVO) or IDEXX Labs (Nasdaq:IDXX), Neogen has a great business but a valuation that goes beyond "healthy" and a fairly sluggish free cash flow margin.

Be Ready, Move Fast
Quality and scarcity are two valid reasons for Neogen to be richly valued. There may also be acquisition expectations at work here as well. Unfortunately, there is only a limited number of likely potential suitors - companies with a presence in food safety like Waters (NYSE:WAT), Mettler Toledo (NYSE:MTD) or Bio-Rad arguably don't need or want the animal business, and companies with animal care businesses (including large pharmas like Sanofi (NYSE:SNY)) don't need the food safety.

In the immediate aftermath of the earnings release, Neogen shares traded as low as $26 before steadily recovering during the day on Thursday. Near the $26 level, it was an interesting play on a company that generates good returns from underserved markets. At $30, it's a harder sale given that it presupposes a lot of top-line growth and improvements in free cash flow production. For now, then, this is a good example of the virtues of being prepared and ready to move - bargains don't always hang around very long. (For related reading, see How To Do Quantitative Analysis On Biotech Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center